Gina Green-Harris is chairperson of the Governor’s Health Equity Council
Dr. Mora Pinzon discusses Alzheimer’s drug lecanemab on Telemundo Wisconsin
Maria Mora Pinzon, MD, MS, FACPM, recently appeared on Telemundo Wisconsin in a news segment discussing FDA approval of the drug lecanemab. The drug gained approval through an accelerated approval process in January 2023. Dr. …
Announcing the IEA Innovation Fund
On behalf of the Initiative to End Alzheimer’s, we are pleased to announce the IEA Innovation Fund, providing project support for researchers at Wisconsin Alzheimer’s Institute and Wisconsin Alzheimer’s Disease Research Center. The fund was …
Video episode of Dementia Matters explores news and research on lecanemab
UW Alzheimer’s disease researchers Dr. Carlsson, Dr. Johnson and Dr. Chin discuss Alzheimer’s drug lecanemab in video episode of Dementia Matters podcast.
Join us for coffee and a chat about healthy aging
Coffee and a Chat, a free, virtual event series. Join in from home – by computer or phone – and listen to health experts and ask questions.
Applications for summer externs are now open!
First-year medical students are invited to apply today.
Dr. Mora Pinzon appointed to assistant professor
Dr. Mora Pinzon’s work focuses on health services research in dementia care, and improving access to dementia care for Latinx individuals.
Dementia Matters episode discusses lecanemab, the latest Alzheimer’s drug to receive FDA accelerated approval
On a recent episode of the Dementia Matters podcast, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Dr. Carlsson discusses approval of Alzheimer’s drug on CBS 58 news
Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA) approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study …
FDA approves Alzheimer’s disease drug lecanemab
On January 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved …